Sexually Transmitted Diseases

ViiV Healthcare has launched a phase 3 study to assess if adults with HIV-1 who have achieved viral suppression on a 3-drug regimen can maintain suppression when switched to a 2-drug regimen.

The FDA has granted pre-market approval for a new HPV test that can detect and identify HPV genotypes that put women at increased risk for cervical cancer.

An international research team finds that targeting the social and risk networks of patients recently diagnosed with HIV is leading them to more patients unknowingly infected with the virus.

Following an outbreak of norovirus in Pyeongchang ahead of the Winter Olympics, health officials are taking steps to stem the outbreak and keep attendees healthy.

In case you missed them, we've compiled the top five infectious disease articles from this past week.

The CDC’s ACIP voted to approve updated adult immunization schedule recommendations for adults aged 19 years or older.

The FDA approves Symfi Lo Tablets for the treatment of HIV-1 in adult and pediatric patients who weigh at least 35 kg.

Ideally, every individual with HIV would be able to receive ART in a timely fashion, but in resource-limited communities, it’s crucial to prioritize those who will most benefit.

Gilead Sciences, Inc.'s Biktarvy has been approved by the FDA for the treatment of those with HIV-1.

Contagion® celebrates its second year this month amid celebrations of bringing in its highest readership traffic to-date.

Researchers from UT Health San Antonio find that exposing the gut to chlamydia protects against subsequent infection in the genital tract as well as other tissues.

An ongoing study aims to confirm that newer ART regimens are as safe for pregnant women living with HIV as they are for their non-pregnant counterparts.

A multinational team of investigators has revealed a link between conflict-induced displacement of people and the spread of HIV within Ukraine.

With about 1 million individuals getting herpes zoster each year in the United States, the best protection against the virus is vaccination.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

Aetna has agreed to a $17 million settlement of a lawsuit centering around the HIV privacy violation that affected approximately 12,000 of the insurer’s customers in 2017.

A recent study finds that younger patients, women, and white individuals infected with HPV-associated cancers have superior survival at 5 years.

The test combines the convenience of the saliva test with the reliability of the blood test.

Three medical centers in the United States have now been approved to perform kidney transplants from living HIV-positive donors to HIV-positive recipients. We break down the risks and benefits.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

University of Western Ontario investigators have found that the genetic diversity of HIV-1 during early infection is greater in the vaginal tract than in the bloodstream.

A new article urges researchers and clinicians to consider the possibility that the rise in oral sex practices could ultimately contribute to female infertility when it comes to chlamydia.

Seeing upwards of 85% of children in the United States each year, dentists are key to promoting HPV prevention methods, but more training and education is needed first.

Teva Pharmaceuticals announces an exclusive launch of a generic version of atazanavir capsules for the treatment of HIV.

In case you missed them, we've compiled the top 5 articles from this past week.

A common birth control shot has been linked with increased risk of HIV infection while NIAID investigators have found that putting ART on pause during a clinical trial might not be as detrimental as first thought.

The CDC releases first comprehensive reports on state progress made in the fight against antibiotic resistance since Congress’ investment in CDC’s Antibiotic Resistance Solutions Initiative.

Investigators from the Massachusetts Institute of Technology, Brigham and Women's Hospital, and Lyndra, have developed a drug capsule that could drastically pare down ART to an easier-to-adhere-to weekly regimen.

A viral therapy developed to target cancer cells, also appears capable of destroying HIV-infected cells.

Investigators from the University of California San Diego Medical School report on the first case of Gardnerella bacteremia in an HIV-positive male following the placement of a urinary catheter.